CJC-1295 vs Ipamorelin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
CJC-1295 is a synthetic GHRH analog with a Drug Affinity Complex (DAC) that binds circulating albumin, extending half-life from 7 minutes to approximately 6-8 days. Enables once-weekly dosing with sustained GH elevation. Phase I/II clinical research status. WADA prohibited under ...
Calculate CJC-1295 dose →Ipamorelin is a synthetic 5-amino acid growth hormone releasing peptide (GHRP) that selectively stimulates pituitary GH secretion without raising cortisol, prolactin, or appetite hormones. Acts on ghrelin receptors (GHSR-1a) for clean pulsatile GH release. Phase I/II research sta...
Calculate Ipamorelin dose →| Parameter | CJC-1295 | Ipamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Research | Extensively Studied | Extensively Studied |
| Half-Life | ~6–8 days (with DAC) | ~2 hours |
| Typical Dose | 1–2 mg | 100–300 µg |
| Frequency | Once weekly or twice weekly | 1–3× daily |
| Route | Subcutaneous | Subcutaneous |
| FDA Status | Not Approved | Not Approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.